Brain Tumor
350
73
97
148
Key Insights
Highlights
Success Rate
84% trial completion
Published Results
34 trials with published results (10%)
Research Maturity
148 completed trials (42% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
8.3%
29 terminated out of 350 trials
83.6%
-2.9% vs benchmark
8%
27 trials in Phase 3/4
23%
34 of 148 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 148 completed trials
Clinical Trials (350)
A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations
Trial Evaluating an Enhanced Physical Activity Intervention to Improve Cognitive Late Effects in Children Treated With Cranial Radiation for Brain Tumors
Home-based Vision Rehabilitation Guided by Brain Imaging
Asciminib With or Without Sildenafil for Brain Tumors
CONVIVO Endomicroscopy
Tolerability and Activity of Brivaracetam (BRV) in Patients With Diffuse Gliomas
European Prospective Investigation Into Childhood Cancer
Fast Brain MRI in Children With Suspected Brain Tumor
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
Evaluating Biomarkers of Cognitive Dysfunction in Patients With Cancer
A Study of Sotorasib in People With Brain Tumors
A Comprehensive Clinical fMRI Software Solution to Enable Mapping of Critical Functional Networks and Cerebrovascular Reactivity in the Brain
Tumor Genomics, Individual Risk Factors, and External Drivers of Health on Health Outcomes for Patients With Meningioma
Brodalumab in the Treatment of Immune-Related Adverse Events
A Study to Measure the Effect of Brain Stimulation on Hand Strength and Function in Patients With Brain Tumors
Perioperative Evaluation of Cerebellar Tumors
A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 Gliomas
LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138)
ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids